While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Nandita Vijayasimha, Bengaluru Monday, July 7, 2025, 08:00 Hrs [IST] ...

Amyloidosis therapeutics market was valued at US$ 2.95 billion in 2024 and is projected to hit the market valuation of US$ 6.37 billion by 2033 at a CAGR of 9.20% during the forecast period 2025–2033.

How was one of the largest U.S. advertisers able to grow within their highly competitive category? How has having an in-house ...